140 related articles for article (PubMed ID: 7689649)
1. Inhibitory effect of NZ-105, a 1,4-dihydropyridine derivative, on cyclic nucleotide phosphodiesterase activity.
Yamashita T; Masuda Y; Sakai T; Tanaka S; Kasuya Y
J Pharm Pharmacol; 1993 Jun; 45(6):530-4. PubMed ID: 7689649
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC
Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089
[TBL] [Abstract][Full Text] [Related]
3. Different sensitivities of Ca2+, calmodulin-dependent cyclic nucleotide phosphodiesterases from rabbit aorta and brain to dihydropyridine calcium channel blockers.
Matsushima S; Tanaka T; Saitoh M; Watanabe M; Hidaka H
Biochem Biophys Res Commun; 1987 Nov; 148(3):1468-74. PubMed ID: 2825687
[TBL] [Abstract][Full Text] [Related]
4. Actions of papaverine on intestinal smooth muscle and its inhibition of cyclic AMP and cyclic GMP phosphodiesterases.
Miyamoto M; Takayanagi I; Ohkubo H; Takagi K
Jpn J Pharmacol; 1976 Feb; (1):114-7. PubMed ID: 177797
[No Abstract] [Full Text] [Related]
5. Cardiovascular selectivity of 1,4-dihydropyridine derivatives, efonidipine (NZ-105), nicardipine and structure related compounds in isolated guinea-pig tissues.
Masuda Y; Miyajima M; Shudo C; Tanaka S; Shigenobu K; Kasuya Y
Gen Pharmacol; 1995 Mar; 26(2):339-45. PubMed ID: 7590084
[TBL] [Abstract][Full Text] [Related]
6. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
7. Cardiac and vascular effects of NZ-105, a novel dihydropyridine derivative, in vitro.
Masuda Y; Iwama T; Yamashita T; Sakai T; Hibi M; Tanaka S; Shigenobu K; Kasuya Y
Arch Int Pharmacodyn Ther; 1991; 314():57-73. PubMed ID: 1668604
[TBL] [Abstract][Full Text] [Related]
8. NZ-105, a new 1,4-dihydropyridine derivative: correlation between dihydropyridine receptor binding and inhibition of calcium uptake in rabbit aorta.
Yamashita T; Masuda Y; Sakai T; Tanaka S; Kasuya Y
Jpn J Pharmacol; 1991 Nov; 57(3):337-48. PubMed ID: 1667534
[TBL] [Abstract][Full Text] [Related]
9. Vasorelaxing and receptor binding properties of NZ-105, a novel dihydropyridine derivative, in isolated rabbit aorta.
Masuda Y; Iwama T; Yamashita T; Sakai T; Hibi M; Tanaka S; Shigenobu K; Kasuya Y
Arch Int Pharmacodyn Ther; 1991; 312():86-103. PubMed ID: 1663336
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists.
Sharma RK; Wang JH; Wu Z
J Neurochem; 1997 Aug; 69(2):845-50. PubMed ID: 9231746
[TBL] [Abstract][Full Text] [Related]
11. Zinc-mediated inhibition of cyclic nucleotide phosphodiesterase activity and expression suppresses TNF-alpha and IL-1 beta production in monocytes by elevation of guanosine 3',5'-cyclic monophosphate.
von Bülow V; Rink L; Haase H
J Immunol; 2005 Oct; 175(7):4697-705. PubMed ID: 16177117
[TBL] [Abstract][Full Text] [Related]
12. Relationship between cyclic nucleotide levels and 5-methyl-6-(4-pyridyl)-2H-1,4-thiazin-3(4H)-one (ZSY-27), a new positive inotropic agent with a vasodilatory action, -induced relaxation of rabbit thoracic aorta.
Yoshioka K; Takayanagi I; Hisayama T
J Pharmacobiodyn; 1989 Nov; 12(11):660-6. PubMed ID: 2561155
[TBL] [Abstract][Full Text] [Related]
13. Properties and drug responsiveness of cyclic nucleotide phosphodiesterases of rat lung.
Fertel R; Weiss B
Mol Pharmacol; 1976 Jul; 12(4):678-87. PubMed ID: 183099
[No Abstract] [Full Text] [Related]
14. Selective inhibition of cyclic AMP and cyclic GMP phosphodiesterases of cardiac nuclear fraction.
Ahluwalia GS; Rhoads AR
Biochem Pharmacol; 1982 Mar; 31(5):665-9. PubMed ID: 6177320
[TBL] [Abstract][Full Text] [Related]
15. Multiple actions of glaucine on cyclic nucleotide phosphodiesterases, alpha 1-adrenoceptor and benzothiazepine binding site at the calcium channel.
Ivorra MD; Lugnier C; Schott C; Catret M; Noguera MA; Anselmi E; D'Ocon P
Br J Pharmacol; 1992 Jun; 106(2):387-94. PubMed ID: 1327380
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents.
Murray KJ; England PJ
Biochem Soc Trans; 1992 May; 20(2):460-4. PubMed ID: 1327922
[No Abstract] [Full Text] [Related]
17. Selective alteration of Ca2+-dependent and Ca2+-independent cyclic nucleotide phosphodiesterase activity in rat cerebral cortex by cyclic nucleotides and their analogs.
Davis CW
Biochim Biophys Acta; 1982 Jul; 705(1):1-7. PubMed ID: 6288105
[TBL] [Abstract][Full Text] [Related]
18. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form.
Lavan BE; Lakey T; Houslay MD
Biochem Pharmacol; 1989 Nov; 38(22):4123-36. PubMed ID: 2480793
[TBL] [Abstract][Full Text] [Related]
19. Mechanism by which psychotropic drugs inhibit adenosine cyclic 3',5'-monophosphate phosphodiesterase of brain.
Levin RM; Weiss B
Mol Pharmacol; 1976 Jul; 12(4):581-9. PubMed ID: 183095
[No Abstract] [Full Text] [Related]
20. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine.
Souness JE; Brazdil R; Diocee BK; Jordan R
Br J Pharmacol; 1989 Nov; 98(3):725-34. PubMed ID: 2480168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
